Special Issue "RNA Drugs in Tumor Microenvironment"
Deadline for manuscript submissions: closed (31 October 2020).
Interests: RNA therapeutics; delivery of nucleic acid therapeutics; aptamer; tumor microenvironment; signal transduction; microRNA; targeted therapy
Special Issues and Collections in MDPI journals
Special Issue in Biomedicines: Engineering Aptamers for Biomedical Applications II
The presence of a complex tumor microenvironment (TME) is recognized to play a crucial role in tumor progression, resistance to therapy, and spreading across the major cancer types, emphasizing the need of precise-targeting therapeutic molecules.
Indeed, RNA-drugs—including siRNAs, miRNAs/antimiRs, lncRNAs, RNA guides (gRNAs), saRNAs, aptamers and ASOs—are emerging as new classes of precise and safe therapeutic drugs for several undruggable disorders, including cancer. On the other hand, several extracellular ncRNAs have recently been implicated in cancer intracellular communication and in TME–tumor interplay.
As such, this Special Issue is intended to highlight the recent advances in understanding the TME–tumor interplay and to underscore the advantages and limitations of using RNA-based therapeutics to target the TME.
Dr. Vittorio de Franciscis
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- cancer therapy
- RNA therapeutic
- tumor microenvironment
- Tumor associated macrophage
- Cancer Associated fibroblast
- extracellular RNA